Trending at Lumira Ventures

XyloCor Therapeutics Presents Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina

Alyssia Watkin Portfolio News, Xylocor Therapeutics, Main Page

Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study Preliminary efficacy data highlight XC001 …

XyloCor Therapeutics Expands Leadership Team with Accomplished Pharmaceutical Executives to Accelerate Clinical Development Programs and Drive Corporate Growth

Alyssia Watkin Portfolio News, Xylocor Therapeutics

XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D.  as Chief Medical Officer and A. Brian Davis as Chief Financial Officer. These experienced pharmaceutical industry executives will …

Lumira completes investment in XyloCor Therapeutics’ Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

admin Portfolio News, Xylocor Therapeutics

XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease – Company closes additional $22.6 million in new financing – – Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as …